Biodesix: Growing Fast While Trading Below Many Diagnostics Peers

Fernanda Galvez Jalil 1.24K Followers Follow Summary Biodesix is gaining momentum in lung diagnostics, with >30% revenue growth and accelerating test volumes. BDSX boasts 80%+ gross margins and improving operating leverage, supporting a credible path to profitability despite ongoing cash burn. The stock trades at a discounted EV/Sales multiple versus peers, despite industry-leading gross margins and robust clinical evidence. I assign BDSX an initial Buy rating, targeting $60–65 per share, reflecting 130% upside based on growth, margins, and valuation. Morsa Images/DigitalVision via Getty Images Investment Thesis Biodesix, Inc. ( BDSX ) is showing strong momentum in its lung diagnostics business, with revenue growing more than 30% and testing volumes increasing even faster. While the company hasn't reached breakeven and cash burn is This article was written by Fernanda Galvez Jalil 1.24K Followers Follow My name is María Fernanda and I'm currently studying an MBA. My inspiration investors are Warren Buffett, Peter Lynch and Terry Smith, so I look for quality companies at a reasonable valuation. I believe that, in the long term, fundamentals are what drive the share price, so I look to predict what a business's earnings per share will do. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BDSX over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.